Zacks Investment Research
03 Aug 2026, 23:46 UTC · 1h ago
ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Misses Revenue Estimates
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
03 Aug 2026, 23:46 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
ClearPoint Neuro (CLPT) reported a quarterly loss of $0.38 per share, missing the Zacks Consensus Estimate of a $0.29 loss. — An earnings miss of 31.03% typically triggers immediate downward pressure on a small-cap stock's price.
-0.60ClearPoint Neuro's quarterly revenue of $10.88 million missed the Zacks Consensus Estimate by 16.31%. — Missing revenue targets suggests slowing growth or operational headwinds, compounding the negative impact of the earnings miss.
-0.50ClearPoint Neuro has failed to surpass consensus EPS estimates for four consecutive quarters. — A persistent trend of missing estimates indicates systemic underperformance, reducing investor confidence in management's guidance.
-0.40Continue reading
6 related stories
Top 1 mover · tap to explore
ClearPoint Neuro currently holds a Zacks Rank #3 (Hold). — A 'Hold' rating is neutral and suggests the market expects the stock to perform in line with its peers.
+0.00Which stocks this story touches
The company reported a quarterly loss that missed consensus estimates and missed revenue expectations.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
